Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

McGuire, Darren K., Marx, Nikolaus, Mulvagh, Sharon L., Deanfield, John E., Inzucchi, Silvio E., Pop-Busui, Rodica, Mann, Johannes F.E., Emerson, Scott S. +10 more·2025·New England Journal of Medicine

DOI 10.1056/nejmoa2501006

Cited by (438)

Items 101–200 of 438

Obesity and Cardiovascular Disease: Mechanistic Insights and Nutritional Management Strategies
Ehud Grossman · 2025 · Nutrients
Anti-inflammatory strategies for patients with atherosclerotic coronary disease
Antonino Imbesi, Antonio Greco, Davide Capodanno · 2025 · Expert Review of Cardiovascular Therapy
Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus
Heinz Drexel, Andreas Festa, Thomas Andersen Schmidt, Bianca Rocca, Dobromir Dobrev, Stefan Agewall, Juan Luis Tamargo, Susanne Kaser · 2025 · European Heart Journal - Cardiovascular Pharmacotherapy
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
Kristine Mace Erlandson, Douglas W. Kitch, Amy Kantor, Pablo Francisco Belaunzarán-Zamudio, Todd Tarquin Brown, Carl J. Fichtenbaum, Sonya L. Heath, Fred R. Sattler, Jordan E. Lake · 2025 · Clinical Infectious Diseases
Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes
Riccardo Candido, Barbara Toffoli, Gabriele Baccichetto, Francesca Marchese, Silvia Carpenè, Sara Gaiotti, Bruno Fabris, Stella Bernardi · 2025 · Acta Diabetologica
Clinical implications of the interaction between metabolic risk factors, coronary artery disease and atrial fibrillation
Leonard Voorhout, Ashley Verburg, Ron Pisters, Jurriën M. ten Berg, Martin E W Hemels · 2025 · Future Cardiology
Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials
Magdaline Zawadka, Erwin Taguiam, Mê‐Linh Lê, Rohan Sanjanwala, Shuangbo Liu, Ashish H. Shah, Setor Kwadzo Kunutsor · 2026 · Diabetes Obesity and Metabolism
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Andreas Papapetropoulos, Stavros Topouzis, Steve P.H. Alexander, Miriam Margherita Cortese-Krott, Zsuzsanna Helyes, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, RA Panettieri, Hemal H. Patel et al. · 2026 · British Journal of Pharmacology
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Oliver Schnell, Arnav Agarwal, Michel Azizi, Dennis A. Ballwieser, Katharine D. Barnard-Kelly, Tadej Battelino, Dennis A. Ballwieser, Matthias Blüher, Elisabetta Bugianesi, Ana Cebrián et al. · 2026 · Cardiovascular Diabetology
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
Johannes F.E. Mann, Sunil V. Badve, Florian M.M. Baeres, Nicolas Belmar, Kirstine Brown‐Frandsen, John B. Buse, Helen Martina Colhoun, John Eric Deanfield, Mads D.M. Engelmann, G. Kees Hovingh et al. · 2026 · The Lancet Diabetes & Endocrinology
Late-life semaglutide treatment slows ageing and extends lifespan in female mice
Yufan Feng, Marine Barthez, Yifei Wang, Yibing Chen, Huixian Qiu, Chih-Ling Wang, Kartoosh Heydari, Melaine Delcroix, Lene Juel Rasmussen, Vilhelm A. Bohr et al. · 2026 · Nature
Now and the Future: Medications Changing the Landscape of Cardiovascular Disease and Heart Failure Management
Thomas Oswald, Steven Coombs, Susan M. Ellery, Alexander Liu · 2025 · Journal of Clinical Medicine
Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease
Subodh Verma, Andrei‐Mircea Catarig, Kim Christian Houlind, Bernhard H. Ludvik, Joakim Nordanstig, Neda Rasouli, Harald Sourij, Sebastian Thomas, Sidse Kjærhus Nørgaard, Marc P. Bonaca · 2025 · Journal of the American College of Cardiology
GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction
Subodh Verma, David A. Hess · 2025 · Cell Metabolism
The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus
De Fano, Michelantonio, Baluganti, Sara, Manco, Marcello, Porcellati, Francesca, Fanelli, Carmine G., Bassotti, Gabrio · 2025 · Nutrients
Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk
Sara Palazzi, Federica Sentinelli, Antonella Zugaro, Sara Nazzarena Morgante, Livia Santarelli, Sandra Melanzi, Annamaria De Mutiis, Deamaria Piersanti, Barbara Macerola, Marco Iezzi et al. · 2025 · Pharmaceuticals
Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease
Harry Economos, Richard J. MacIsaac · 2025 · World Journal of Nephrology
Therapie des Typ-2-Diabetes
Baptist Gallwitz, Jens Aberle, Andreas L. Birkenfeld, MONIKA KELLERER, Harald H. Klein, Rüdiger Landgraf, Dirk Müller‐Wieland, Karsten Müssig, Michael Albrecht Nauck, Erhard G. Siegel et al. · 2025 · Diabetologie und Stoffwechsel
Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN
Lixin Guo, Shan Ding, Weihao Wang, Hanxi Zhang, Shaojun Dai, Chengwei Li, Yuan Yuan, Adam Stefański, Irina Jouravskaya, TAMMY D. FORRESTER · 2025 · EClinicalMedicine
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome
Sonal Rajesh Kumar, John E. Anderson, Andrea D. Coviello, F. Lopez-Jimenez, George L. Bakris · 2026 · JACC Advances
Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease
Shuai Hu, Kyung Lee, Cijiang He, Ying Fan · 2026 · Clinical Journal of the American Society of Nephrology
Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review
Jorge E. Rico-Fontalvo, Rodrigo Daza-Arnedo, Alicia Ester Elbert, Ricardo Correa‐Rotter, Eliana Diná-Batlle, Eduardo Lorca, Thyago Proença de Moraes, Vicente Sánchez-Polo, Carlos Esteban Builes-Montaño · 2026 · Diabetes Therapy
GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence
Valentini Samanidou, Konstantinos Tsamis, Alexandr Ceasovschih, Theocharis Koufakis, Dimitrios Patoulias, Evangelos C. Rizos, Manfredi Rizzo, Haralampos J. Milionis, Fotios Barkas · 2026 · Journal of Central Nervous System Disease
Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis
M Ahmed, Tallal Mushtaq Hashmi, Maryam Shahzad, Rohma Zia, Hadiah Ashraf, Raheel Ahmed, Muhammad Owais Rashid, Stephen John Greene, Robert John Mentz, Marat Fudim et al. · 2026 · European Heart Journal - Quality of Care and Clinical Outcomes
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Michelantonio De Fano, Line L. Haurum, Christine Rode Andreasen, Francesca Porcellati, Andreas Andersen · 2026 · Diabetes Obesity and Metabolism
Beyond weight loss: multisystem benefits of obesity medications
Mesut Savas, Susanne Kuckuck, Mariëtte R. Boon, Elisabeth F. C. van Rossum · 2026 · The Lancet Diabetes & Endocrinology
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Konstantinos Stefanakis, Paschalis Karakasis, Dimitra Vasdeki, Djordje S. Popovic, Dimitrios Patoulias, Manfredi Rizzo, Christos Socrates Mantzoros · 2026 · Endocrine Reviews
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Leonardo De Luca, Claudio Bilato, Alessandro Navazio, Marco Corda, Massimo Milli, Pietro Scicchitano, Massimo Di Marco, Carmine Riccio, Giovanna Geraci, Attilio Iacovoni et al. · 2025 · European Heart Journal Supplements
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference
Vashma Junaid, Colin Andrew Hinkamp, Arsalan Hamid, Ali Bin Abdul Jabbar, Abdul Mannan Khan Minhas, Maha Inam, Adeel Akbar Khoja, Sana Sadiq Sheikh, Chayakrit Krittanawong, Elizabeth M. Vaughan et al. · 2025 · Current Atherosclerosis Reports
Evaluation and Management of Obesity in Chronic Kidney Disease
Allon N. Friedman · 2025 · Journal of Renal Nutrition
Seeking Multiorgan Benefits with Cardiovascular–Kidney–Metabolic Drug Therapy
Faiez M. Zannad · 2025 · New England Journal of Medicine
Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes
Maxwell Salvatore, Bingyu Zhang, Huilin Tang, Yiwen Lu, Dazheng Zhang, Ting Zhou, Yuan Lu, Anastassia Amaro, Marylyn DeRiggi Ritchie, Yong Chen · 2025 · medRxiv
GLP-1 Receptor Agonists Help Legs
Ronald Goldenberg, Subodh Verma · 2025 · Diabetes Care
Design Matters: How Methodological Decisions May Have Shaped the Findings of CREST-2
Marc I. Chimowitz · 2026 · Stroke
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Karthik Murugadoss, AJ Venkatakrishnan, Christopher J. Gregg, Venky Soundararajan · 2026 · medRxiv
Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study)
Óscar Moreno, Antonio Tejera‐Muñoz, Rubén Carreño-Valdivia, María Rodríguez-Bedoya, Cristina Guillén-Morote, Ada María Roldán‐Sánchez, Mariano Andrés · 2025 · Seminars in Arthritis and Rheumatism
Oral Semaglutide: A Step Forward in Cardiovascular Risk Management for Type 2 Diabetes
Eder Luna Ceron, Lakshmi Prasanna Vaishnavi Kattamuri, Sparsha Reddy Duvvuru, Debabrata Mukherjee · 2025 · Cardiovascular & Haematological Disorders - Drug Targets
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando M. A. Giuffrida, Larissa Neto Espíndola, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Cláudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, Antônio Carlos Palandri Chagas et al. · 2025 · Arquivos Brasileiros de Cardiologia
GLP-1 medicine and non-arteritic anterior ischemic optic neuropathy: Literature review and perspectives
Jia Nuo Feng, Yanming Chen, Tianru Jin · 2025 · Metabolism and Diseases
The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial
Katy S. Lehenbauer, Adam J. Nelson, Savina Nodari, Aaron Leonid Sverdlov, Josephine Harrington · 2025 · Heart Failure Reviews
Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert, The UK Thyroid Cancer Study Group · 2025 · Clinical Endocrinology
Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy
Yan Miao, Pan He, Dan-Yu Wang, Lei Yan, Huixia Cao, Feng-Min Shao · 2026 · World Journal of Diabetes
Cardiovascular Science, Medicine, and Society: The Brave New World
Jessica A. Regan, Melissa H. Laitner, Victor J. Dzau · 2026 · Journal of the American College of Cardiology
Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
Cyrille K. Cornelio, Kevin Cowart, Janelle B. Perkins, Mohammed Alomar, Ricardo Pineda-Gayoso, Aimon Chantara Miranda, Anh T. Phan, Raechel T. White · 2026 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Prerana Ramadurgum, Kunal M. Sharma, Alec Pinon, Lakshmi Prasanna Vaishnavi Kattamuri, Monica Botros · 2026 · Current Cardiology Reports
Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis
Klara Rachel Klein, Anna Menacher, John B. Buse, Johannes F.E. Mann, Katherine R. Tuttle, Kajsa Kvist, Margit Riis Andersen, Manuel Mayrdorfer, Ildiko Lingvay · 2026 · Diabetes Care
Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases
Derin Karacabeyli, Diane V. Lacaille · 2026 · Rheumatology
Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration—A Narrative Review
Shayan Khan, W. Herbst, Farbod Zahedi Tajrishi, Sonali Notani, Alexander Knight, Zina Jamil, Keith C. Ferdinand · 2026 · Biomedicines
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Caterina Conte, Anastassia Amaro · 2026 · Current Diabetes Reports
The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis
Kezia Peter, Ocin Roka, Emma Sepp, Maya Warburton, Jufen Zhang, Simon C. Cork · 2026 · Cardiovascular Diabetology – Endocrinology Reports
GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos-Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Αlexandros Briasoulis, Kimon S. Stamatelopoulos, Theodosios D. Filippatos · 2026 · Diabetes Obesity and Metabolism
Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis
Federica Marzano, Stefania Paolillo, Paola Gargiulo, Ciro Cotticelli, Mariafrancesca Di Santo, Ermanno Nardi, Giuseppe Maria Abbellito, Laura Liccardi, Fabrizio Perrone Filardi, Dario Bruzzese et al. · 2026 · Cardiovascular Diabetology
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease
Sadiya S. Khan, Chiadi E. Ndumele, Nicole Martin Bhave, Roger Scott Blumenthal, Josef Coresh, Xiaoning Huang, Joshua J. Joseph, Amit Khera, Jennifer E. Ho, Donald M. Lloyd‐Jones et al. · 2026 · Journal of the American College of Cardiology
Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy
Libin Qiu, Jinpeng Liu, Nana Hu · 2026 · Frontiers in Endocrinology
Peripheral artery disease: advances in medical therapy
Fernando Garagoli, Leandro N. Slipczuk, Michael David Shapiro, Marc P. Bonaca, Deepak L. Bhatt · 2026 · European Heart Journal
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Pablo Mora, Vanita R. Aroda, Marisse Asong, Matthias Blüher, Amanda‐Louise Fenger Carlander, Morten Kaltoft, Louise Nygaard Vilsen, Julio Rosenstock · 2026 · The Lancet
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Janani Rangaswami, Kevin Bryan Lo, Chiadi E. Ndumele · 2026 · Nature Reviews Nephrology
Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy)
Óscar Moreno, Rebeca Reyes‐García, Cristina Guillen-Morote, Viyey Kishore Doulatram‐Gamgaram, Carlos Casado Cases, Nieves Arias Mendoza, Cristina Tejera Pérez, Jersy Cárdenas‐Salas, Sandra Martínez‐Fuster, Beatriz Lardiés‐Sánchez et al. · 2025 · Clinical Kidney Journal
The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
Sihua Wang, Duncong Fan, Qinhong Yao, Xiaojie Sun · 2025 · Diabetes Obesity and Metabolism
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
2025 · New England Journal of Medicine
The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents
Konstantinos Malas, Salman Kazmi, Yu Mi Kang, Darren K. McGuire · 2025 · Expert Opinion on Pharmacotherapy
Effect of semaglutide on mortality and cardiovascular events in patients at high cardiovascular risk: an updated systematic review and meta-analysis
Marco Spagnolo, Davide Capodanno · 2025 · European Journal of Preventive Cardiology
2024 Taiwan clinical practice guideline for diabetic kidney disease – an executive summary
Sheng‐Chiang Su, Tieng-Chun Chang, Yi‐Wen Chiu, Chih‐Hsun Chu, Yueh‐Han Hsu, Chin‐Sung Kuo, Chun‐Chuan Lee, Ming‐Hsun Lin, Chun‐Liang Lin, Yuh-Feng Lin et al. · 2025 · Journal of the Formosan Medical Association
Adiposity-based Chronic Diseases and the Therapeutic Role of Glucagon-like Peptide-1 Receptor Agonists
RAJIV R. KOVIL, Tejas Shah, Snehal Tanna, Vijay B Negalur, SONALI A. PATANGE, Ami Sanghvi, PC Manoria, MANGESH HARIHAR TIWASKAR, DAKSHATA A. PADHYE, Alpana Sowani et al. · 2025 · International Journal of Diabetes and Technology
Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
Dario Giugliano, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito · 2025 · Diabetes Obesity and Metabolism
Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM
Samit Ghosal, Anuradha Ghosal · 2025 · Diabetes Metabolic Syndrome and Obesity
Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Sihua Tan, Yangguang Yin, J. Lu · 2025 · Frontiers in Cardiovascular Medicine
Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
Kevin Cowart, Cyrille K. Cornelio, Benedicta O. Ansong, John Petrilli, Nicholas W. Carris · 2025 · Diabetes Obesity and Metabolism
Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection
Anastasios Tentolouris, Christos Siafarikas, Ioannis Ntanasis‐Stathopoulos, Ioanna A. Anastasiou, Eirini Kalara, Αlexandros Briasoulis · 2026 · Primary care diabetes
Benchmarking weight loss and survival benefits after gastric bypass: a long-term cohort study
Ramsey Michael Dallal, Noah Streitfeld, Zaid Haddadin, Alec C. Beekley, Talar Tatarian, Marc Neff, Janine V. Kyrillos, Aditya Das, Alfred Trang · 2026 · Surgery for Obesity and Related Diseases
Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials
Vikash Jaiswal, Yusra Mashkoor, Vamsikalyan Borra, Asmita Gera, Nirmit Patel, Sahas Reddy Jitta, YUSRA MINAHIL NASIR, Prachi Sharma, Jishanth Mattumpuram · 2026 · Reviews in Cardiovascular Medicine
The year in cardiovascular medicine 2025: the top 10 papers in diabetes and metabolic disorders
Francesco Cosentino, Nikolaus Marx, Christopher Paul Cannon · 2026 · European Heart Journal
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis
Meijun Wang, Yu-nuo Jiang, Pei-pei Li, Yuan-Jie Wu · 2026 · Diabetes Metabolic Syndrome and Obesity
Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations
John W. Ostrominski, Janinne Ortega-Montiel, Deborah J. Wexler, Brendan M. Everett, SARA JANE CROMER, Caroline F. Byrne, Robert J. Glynn, Julie M. Paik, Elisabetta Patorno · 2026 · Diabetes Care
A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome
Lu Ye, Pusong Tang, Haixu Wan, Xing Zhong, Xin Chen, Changzhao Liu, Rui Huang · 2026 · Drug Design Development and Therapy
Bacteroides acidifaciens exacerbates cardiac ischemia/reperfusion injury via the microbial-host isozyme DPP4
Junxia Zhang, Changyun Liu, Yupeng Wang, Yusi Chen, Haibao Shang, Wen Zheng, Li Jin, Peng Xie, Yingjia Li, Yahan Liu et al. · 2026 · Cell Host & Microbe
Retatrutide-Induced Intractable Diarrhea
Opeyemi Komolafe · 2026 · Annals of Internal Medicine Clinical Cases
Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP ‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials
Masashi Hasebe, Hisashi Kamido, Chen‐Yang Su, Yamato Keidai, Daisuke Yabe, Satoshi Yoshiji · 2026 · Diabetes Obesity and Metabolism
Erectile dysfunction as an early biomarker of cardiovascular toxicity: Mechanisms and clinical implications
Rahul Jaiswal, Nikita Devi, Lakshman Chauhan, Sageer Ahmad, Supriya Pandey, Kartik Tiwari, Ashok Kumar Yadav, Asad Ali, Rupali Jaiswal, Reetu et al. · 2026 · Microvascular Research
Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis
Giuliana G. Repetti, E. Dale Abel, Peter Tontonoz, Tamer Sallam · 2026 · Circulation Research
GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) – beyond weight loss: a condensed scientific review
Elyzabeth Roy, Marie-Claude Parent, Anique Ducharme · 2026 · Drugs in Context
Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency
Marco Infante, Camillo Ricordi, Francesca Pacifici, Donatella Pastore, Raffaele Infante, Massimiliano Caprio, Francesca Chiereghin, Alessandro De Stefano, Giulia Frank, Alessio De Rose et al. · 2026 · Nutrients
Cardiovascular Outcomes With Tirzepatide Versus GLP ‐1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta‐Analysis
João Pedro Machado Ribeiro Jacintho Silva, B Nogueira, Deborah Lomelino Sartori, J A R da Silva, Lucca Biagio Argenton Sciota, Oscar Inácio de Mendonça Bisneto, Wilton Francisco Gomes · 2026 · Diabetes Obesity and Metabolism
Post Hoc Analyses of DKD Clinical Trials in Ethnic Minorities (Asian, Hispanic, Black) Narrative Review
Li‐Li Hsiao, Steven G. Coca, Samuel H. Fantaye, Francisca M. Acosta, Carolina Solis‐Herrera · 2025 · Clinical Therapeutics
Oral Semaglutide Therapy Reduces Cardiovascular Events in Patients with Type 2 Diabetes: Deciphering the Soul of the Study
Ishwarlal Jialal, Samuel T. Olatunbosun · 2025 · Journal of Clinical Medicine
From Glucose to Limb Salvage: New Therapeutic Frontiers to Redefine Outcomes in Diabetic Foot Disease
Cyaandi Dove, Rodica Pop‐Busui · 2026 · Diabetes Care
HFpEF Without Obesity: Fallen Off the Radar?
Adam J. Nelson, Neha Jadeja Pagidipati · 2025 · Journal of Cardiac Failure
Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials
Maria Ahmad, Ayesha Sikandar, Abdul Aziz, Wisam Bachar Al Sumodi, Aakash Hans, Muhammad Usman · 2025 · Cureus
SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes
Christine Rode Andreasen, Tina Vilsbøll · 2025 · Med
Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists
Phuc Nguyen Tran-Duc, Kyung‐Sun Heo · 2025 · CardioMetabolic Syndrome Journal
Pharmacotherapy development and trends in lipidology: An expert discussion
Michael H. Davidson, Kevin Carl Maki · 2025 · Journal of clinical lipidology
Renal hyperfiltration with and without metabolic syndrome: differential implications for cardiovascular events, kidney failure, and mortality
Yu Ho Lee, Dae Kyu Kim, Jin Sug Kim, Su Jin Jeong, Kyung Hwan Jeong, Hyeon Seok Hwang · 2025 · Frontiers in Nutrition
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando M. A. Giuffrida, Larissa Neto Espíndola, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Cláudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, Antônio Carlos Palandri Chagas et al. · 2025 · Arquivos Brasileiros de Cardiologia
Cardiometabolic and Diabetes Management in Older Adults
William Marion, Ian J. Neeland · 2026 · Clinics in Geriatric Medicine
Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes
Larissa Araújo de Lucena, Deivyd V. S. Cavalcante, Marcela Vasconcelos Montenegro, Larissa Calixto Hespanhol, William Santos de Oliveira, Juliana Queiroz Vasconcelos Muniz, Sruti V. Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Martins Giorgi · 2026 · Current Diabetes Reports
Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications
Victoria Odeleye, Nikita Singh, Swotantra Gautam, Elizabeth Shannon, William Matthew Bibb, Mary McClure, Timir K. Paul · 2026 · Current Cardiology Reports
Oral Glucagon-Like Peptide-1 Therapies—Moving Beyond Needles
Sadiya S. Khan · 2026 · JAMA Cardiology
Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide
Kohzo Takebayashi, Yurina Iemura, Mototaka Yamauchi, Kenji Hara, Takafumi Tsuchiya, Shigeki Machida, Koshi Hashimoto · 2026 · Diabetology International
Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials
D. Müller-Wieland, Darren K. McGuire, Abraham Michael Lincoff, John B. Buse, Johannes F.E. Mann, Silvio E. Inzucchi, Rodica Pop‐Busui, Sharon L. Mulvagh, Scott S. Emerson, Neil R Poulter et al. · 2026 · Diabetes Obesity and Metabolism
Cardiovascular outcome trials (CVOTs) in cardiorenal metabolic medicine: a decade of transformative progress (2016–2026)
Song Wen, Congcong Wang, Zhimin Xu, Lijiao Chen, Yanju He, Yishu Ren, Yue Yuan, Yanyan Li, Meiyuan Dong, Min Gong et al. · 2026 · Cardiovascular Diabetology